ERBB2 emerges as a new target for colorectal cancer.
Cancer Discov
| Authors | |
| Keywords | |
| Abstract | ERBB2 mutations and amplifications are present in 7% of colorectal cancers. The presence of these alterations may be a marker of resistance to anti-EGFR therapy and, more importantly, could help identify patients who would benefit from ERBB2-directed therapy. |
| Year of Publication | 2015
|
| Journal | Cancer Discov
|
| Volume | 5
|
| Issue | 8
|
| Pages | 799-801
|
| Date Published | 2015 Aug
|
| ISSN | 2159-8290
|
| URL | |
| DOI | 10.1158/2159-8290.CD-15-0730
|
| PubMed ID | 26243861
|
| PubMed Central ID | PMC4527096
|
| Links | |
| Grant list | K08 CA134931 / CA / NCI NIH HHS / United States
P01 CA098101 / CA / NCI NIH HHS / United States
P01CA098101 / CA / NCI NIH HHS / United States
|